Recursion appointed Najat Khan, PhD, as CEO effective January 1, signaling a strategic shift from platform building to delivering clinical proof points. The leadership change follows the company’s earlier M&A activity and pipeline rationalization; outgoing CEO Chris Gibson will move to board chair. That move echoes a broader pattern: surveys and industry data show that 'heavy AI' adoption is spreading across biopharma roles — with nearly half of respondents reporting routine AI usage at work. For AI‑first companies, the pressure is to convert computational leads into late‑stage clinical evidence. Investors and industry watchers will track whether management changes at AI‑centred biotechs accelerate the translation of models into approved medicines and commercial value.